[go: up one dir, main page]

AR129445A1 - USE OF TNF-a BINDING PROTEINS AND IL-7 BINDING PROTEINS IN MEDICAL TREATMENT - Google Patents

USE OF TNF-a BINDING PROTEINS AND IL-7 BINDING PROTEINS IN MEDICAL TREATMENT

Info

Publication number
AR129445A1
AR129445A1 ARP230101329A ARP230101329A AR129445A1 AR 129445 A1 AR129445 A1 AR 129445A1 AR P230101329 A ARP230101329 A AR P230101329A AR P230101329 A ARP230101329 A AR P230101329A AR 129445 A1 AR129445 A1 AR 129445A1
Authority
AR
Argentina
Prior art keywords
tnf
binding proteins
binding protein
binding
bispecific antibodies
Prior art date
Application number
ARP230101329A
Other languages
Spanish (es)
Inventor
Claire Ashman
Gerben Bouma
Edward Thomas Coulstock
David Dixon
Stephanie Hopley
Alan Peter Lewis
John Lich
Peter Joseph Morley
Sunil Nagpal
Jessica Lynn Neisen
Daniel Rycroft
Jeremy Sokolove
Joseph R Tickle
Joel Tocker
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR129445A1 publication Critical patent/AR129445A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación se refiere al uso de proteínas de unión a TNF-a y proteínas de unión a interleucina 7 (IL-7) en el tratamiento de afecciones autoinmunitarias y/o inflamatorias. La divulgación también se refiere a métodos para tratar enfermedades con proteínas de unión a TNF-a y proteínas de unión a IL-7. La divulgación se refiere además a anticuerpos biespecíficos que se unen a TNF-a e IL-7, los usos de tales anticuerpos biespecíficos, las composiciones farmacéuticas que comprenden tales anticuerpos biespecíficos y los métodos para su fabricación. Reivindicación 7: La proteína de unión a IL-7 y TNF-a de una cualquiera de las reivindicaciones 1 a 6, caracterizada porque la proteína de unión también comprende mutaciones Fc para prolongar la semivida. Reivindicación 9: La proteína de unión a IL-7 y TNF-a de una cualquiera de las reivindicaciones 1 a 8, caracterizada porque la proteína de unión también comprende mutaciones Fc para desactivar la función efectora. Reivindicación 22: Una línea celular diseñada para expresar la proteína de unión a IL-7 y TNF-a de una cualquiera de las reivindicaciones 1 a 16 y 21.The present disclosure relates to the use of TNF-a binding proteins and interleukin 7 (IL-7) binding proteins in the treatment of autoimmune and/or inflammatory conditions. The disclosure also relates to methods of treating diseases with TNF-a binding proteins and IL-7 binding proteins. The disclosure further relates to bispecific antibodies that bind to TNF-a and IL-7, uses of such bispecific antibodies, pharmaceutical compositions comprising such bispecific antibodies, and methods for their manufacture. Claim 7: The IL-7 and TNF-a binding protein of any one of claims 1 to 6, characterized in that the binding protein also comprises Fc mutations to prolong half-life. Claim 9: The IL-7 and TNF-a binding protein of any one of claims 1 to 8, characterized in that the binding protein also comprises Fc mutations to disable effector function. Claim 22: A cell line engineered to express the IL-7 and TNF-a binding protein of any one of claims 1 to 16 and 21.

ARP230101329A 2022-05-27 2023-05-24 USE OF TNF-a BINDING PROTEINS AND IL-7 BINDING PROTEINS IN MEDICAL TREATMENT AR129445A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263346516P 2022-05-27 2022-05-27

Publications (1)

Publication Number Publication Date
AR129445A1 true AR129445A1 (en) 2024-08-28

Family

ID=86692927

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101329A AR129445A1 (en) 2022-05-27 2023-05-24 USE OF TNF-a BINDING PROTEINS AND IL-7 BINDING PROTEINS IN MEDICAL TREATMENT

Country Status (3)

Country Link
AR (1) AR129445A1 (en)
TW (1) TW202413441A (en)
WO (1) WO2023227641A1 (en)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ES2897506T3 (en) 2003-01-09 2022-03-01 Macrogenics Inc Identification and modification of antibodies with variant Fc regions and methods of using them
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
UY32038A (en) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd IMMUNOBLOBULINAS ANTI-CD127 AND ITS USES
MX2012006243A (en) 2009-11-30 2012-10-15 Janssen Biotech Inc Antibody fc mutants with ablated effector functions.
HUE047228T2 (en) 2010-11-05 2020-04-28 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2925785A4 (en) 2012-11-28 2016-11-16 Zymeworks Inc HEAVY-DUTY LIGHT-CHAINS PAIRS OF IMMUNOGLOBULIN HANDLING AND THEIR USES
US11306156B2 (en) 2014-05-28 2022-04-19 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
CN116396393A (en) 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 Antigen binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
MX2021015762A (en) * 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc COMPOSITIONS.
CA3199648A1 (en) * 2020-12-02 2022-06-09 Gerben BOUMA Il-7 binding proteins and their use in medical therapy

Also Published As

Publication number Publication date
WO2023227641A1 (en) 2023-11-30
TW202413441A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
DOP2022000166A (en) ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND THESE USES
CL2020002144A1 (en) Multispecific binding proteins that bind to cd33, nkg2d and cd16 and methods of use, (request hna 2143)
BR112022019020A2 (en) MASKED IL12 FUSION PROTEINS AND METHODS OF USING THEM
BR112018067458A2 (en) antibodies to tigit
CL2017002767A1 (en) New specific proteins for cd137.
AR109264A1 (en) UNION PROTEINS SIMILAR TO BIESPECTIFIC ANTIBODY THAT SPECIFICALLY JOIN CD3 AND CD123
AR086272A2 (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND THEIR USES
BR112012019881A2 (en) fibronectin-based structural domain proteins that bind to il-23
EA201290570A1 (en) CONSTRUCTIONS CONNECTING WITH RON AND METHODS OF THEIR USE
EA201790087A1 (en) COVALENTLY ASSOCIATED DIATELS, possessing immunoreactivity with PD-1 and LAG-3, and methods of their use
AR095614A1 (en) BISPS SPECIFIC HETERODIMERIC ANTIBODIES
EA200870274A1 (en) Peptides blocking the binding of IgG C FcRn
CL2008002668A1 (en) Antibody that specifically binds to thymic stromal lymphopoietin polypeptide (tslp); pharmaceutical composition comprising it; nucleic acid, expression vector, cell comprising it; hybridoma; production method of the antibody; use to treat tslp-related inflammatory disorder or tslp-related fibrotic condition.
AR059604A1 (en) ANTIBODIES AGAINST IL-22 HUMAN AND USES FOR THE SAME
AR092089A1 (en) INTERLEUQUINA-2 FUSION PROTEINS AND USES OF THE SAME
AR063086A1 (en) HUMAN ANTIBODIES THAT JOIN CXCR4 AND USES OF THE SAME
AR069290A1 (en) MONOCLONAL ANTIBODIES THAT JOIN THE HGM -CSF (STIMULATING FACTOR OF THE COLONY OF GRANULOCITOS-MACROFAGOS) AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM
AR103714A1 (en) SPECIFIC PROTEINS FOR PIOVERDINE AND PIOQUELINE
CL2024003895A1 (en) Proteins that bind to nkg2d, flt3, and cd16; pharmaceutical composition; and their use.
BR112018010937A2 (en) cytokine grafted antibody compositions and methods of use for immunoregulation
AR127162A1 (en) PROTEINS THAT BIND NKG2D, CD16 AND BAFF-R
MX2021005151A (en) Novel agonistic anti tnfr2 antibody molecules.
CL2021000316A1 (en) Multispecific binding proteins that bind to bcma, nkg2d and cd16 and methods of use
CR20240181A (en) CD19-BINDING MOLECULES AND THEIR USES
CL2022003320A1 (en) Proteins comprising cd3 antigen binding domains and uses thereof.